Investigating Neutrophil Extracellular Traps in Kidney Stones
Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone, Cross-section, Non-drug Clinical Study-Analysis of Biological Fluids (Residual Human Body Material (RHBM)): STONET's Project
This study is trying to understand how certain immune cells, called neutrophils, might be linked to kidney stones and kidney damage by looking at blood and urine samples from patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Brugmann University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06412822 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the role of neutrophil extracellular traps (NETs) in patients with kidney stones, both acute and chronic kidney disease. It involves blood and urine sampling to analyze the presence and impact of NETs and their potential contribution to inflammation and cell necrosis in kidney conditions. The study aims to clarify whether neutrophils undergo cell death during NET release and how this process may relate to kidney injury. By examining these mechanisms, the research seeks to enhance our understanding of kidney stone pathology.
Who should consider this trial
Good fit: Ideal candidates include patients with acute or chronic kidney disease, with or without kidney stones, who are receiving care at CHU Brugmann.
Not a fit: Patients with a history of malignancy or those currently participating in another clinical trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into kidney stone formation and potential therapeutic targets for preventing kidney damage.
How similar studies have performed: While the role of NETs in various diseases is being explored, this specific investigation into NETs related to kidney stones is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients with acute and/or chronic kidney disease, with stones or without stones, ambulatory or hospitalized in CHU Brugmann Brugmann. Exclusion Criteria: * Malignancy or treatment for malignancy within 12 months prior to Screening with the exception of localized basal cell or squamous cell skin cancer. Note: Subjects whose malignancy is in remission and who are on a stable dose of chronic suppressive or maintenance therapy are not excluded. * Psychological illness or condition, interfering with the patient's compliance or ability to understand the requirements of the study. * Participation in another clinical trial.
Where this trial is running
Brussels
- CHU Brugmann — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Agnieszka POZDZIK — CHU Brugmann
- Study coordinator: Agnieszka POZDZIK
- Email: Agnieszka.POZDZIK@chu-brugmann.be
- Phone: 3224752639
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.